T30
Tirzepatide 30mg Peptide
Each order comes with five Syringes, Alcohol pads, and 3ml BAC water.
----
Tirzepatide is a once-weekly injectable medication primarily used for the treatment of type 2 diabetes and obesity. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, meaning it mimics the effects of both of these hormones to regulate blood sugar levels and promote weight loss.
For research purposes only.
Mechanism of Action:
GIP Activation: Enhances insulin secretion, reduces glucagon levels, and may improve fat metabolism.
GLP-1 Activation: Delays gastric emptying, increases insulin secretion, suppresses appetite, and reduces glucagon secretion.
Uses:
Approved for type 2 diabetes to improve glycemic control (brand name Mounjaro).
Approved for weight management in adults with obesity or overweight with at least one weight-related condition (brand name Zepbound).
Benefits:
Significant blood sugar reduction in type 2 diabetes patients.
Effective in promoting weight loss, often exceeding 20% in clinical trials.
May have cardiovascular benefits, though ongoing research is examining its full effects.
Side Effects:
Common: Nausea, vomiting, diarrhea, decreased appetite, and constipation.
Serious: Risk of pancreatitis, gallbladder disease, thyroid tumors (based on animal studies), and severe gastrointestinal issues.
Comparison to Other GLP-1 Drugs (e.g., Semaglutide):
Tirzepatide, a dual action (GIP + GLP-1) may offer greater weight loss and blood sugar control compared to semaglutide (a GLP-1-only agonist).
Some studies suggest tirzepatide leads to faster and more sustained weight loss than semaglutide.
Dosage & Administration:
Injected once weekly, starting at a low dose and titrated up to minimize side effects.
Typically self-administered via a prefilled pen.
Who Should Avoid It?
Individuals with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2 (MEN2).
Those with severe gastrointestinal disorders or a history of pancreatitis.
For research purposes only.